other material
confidence high
sentiment neutral
materiality 0.60
Aadi Bioscience enters $75M ATM equity offering agreement with Cowen
Whitehawk Therapeutics, Inc.
- ATM facility allows Aadi to sell up to $75M in common stock at its discretion.
- Cowen will receive 3.0% commission on gross proceeds from any shares sold.
- Sales will be made on Nasdaq under existing shelf registration statement (S-3).
- Aadi has no obligation to sell any shares; program effective March 17, 2022.